Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

Zachary A. Cooper, Alexandre Reuben, Christine N. Spencer, Peter A. Prieto, Jacob L. Austin-Breneman, Hong Jiang, Cara Haymaker, Vancheswaran Gopalakrishnan, Michael T. Tetzlaff, Dennie T. Frederick, Ryan J. Sullivan, Rodabe N. Amaria, Sapna P. Patel, Patrick Hwu, Scott E. Woodman, Isabella C. Glitza, Adi Diab, Luis M. Vence, Jaime Rodriguez-Canales, Edwin R. ParraIgnacio I. Wistuba, Lisa Coussens, Arlene H. Sharpe, Keith T. Flaherty, Jeffrey E. Gershenwald, Lynda Chin, Michael A. Davies, Karen Clise-Dwyer, James P. Allison, Padmanee Sharma, Jennifer A. Wargo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

ABSTRACT: We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, and we performed studies to test the hypothesis that clinical patterns and immune infiltrates differ at progression on these treatments. We observed rapid clinical progression kinetics in patients on targeted therapy compared to immune checkpoint blockade. To gain insight into possible immune mechanisms behind these differences, we performed deep immune profiling in tumors of patients on therapy. We demonstrated low CD8+T-cell infiltrate on targeted therapy and high CD8+T-cell infiltrate on immune checkpoint blockade at clinical progression. These data have important implications, and suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.

Original languageEnglish (US)
JournalOncoImmunology
Volume5
Issue number3
DOIs
StatePublished - Mar 3 2016

Fingerprint

Melanoma
Therapeutics
T-Lymphocytes

Keywords

  • BRAF
  • CTLA-4
  • Immune checkpoint blockade
  • melanoma
  • PD-1
  • targeted therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. / Cooper, Zachary A.; Reuben, Alexandre; Spencer, Christine N.; Prieto, Peter A.; Austin-Breneman, Jacob L.; Jiang, Hong; Haymaker, Cara; Gopalakrishnan, Vancheswaran; Tetzlaff, Michael T.; Frederick, Dennie T.; Sullivan, Ryan J.; Amaria, Rodabe N.; Patel, Sapna P.; Hwu, Patrick; Woodman, Scott E.; Glitza, Isabella C.; Diab, Adi; Vence, Luis M.; Rodriguez-Canales, Jaime; Parra, Edwin R.; Wistuba, Ignacio I.; Coussens, Lisa; Sharpe, Arlene H.; Flaherty, Keith T.; Gershenwald, Jeffrey E.; Chin, Lynda; Davies, Michael A.; Clise-Dwyer, Karen; Allison, James P.; Sharma, Padmanee; Wargo, Jennifer A.

In: OncoImmunology, Vol. 5, No. 3, 03.03.2016.

Research output: Contribution to journalArticle

Cooper, ZA, Reuben, A, Spencer, CN, Prieto, PA, Austin-Breneman, JL, Jiang, H, Haymaker, C, Gopalakrishnan, V, Tetzlaff, MT, Frederick, DT, Sullivan, RJ, Amaria, RN, Patel, SP, Hwu, P, Woodman, SE, Glitza, IC, Diab, A, Vence, LM, Rodriguez-Canales, J, Parra, ER, Wistuba, II, Coussens, L, Sharpe, AH, Flaherty, KT, Gershenwald, JE, Chin, L, Davies, MA, Clise-Dwyer, K, Allison, JP, Sharma, P & Wargo, JA 2016, 'Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma', OncoImmunology, vol. 5, no. 3. https://doi.org/10.1080/2162402X.2015.1136044
Cooper, Zachary A. ; Reuben, Alexandre ; Spencer, Christine N. ; Prieto, Peter A. ; Austin-Breneman, Jacob L. ; Jiang, Hong ; Haymaker, Cara ; Gopalakrishnan, Vancheswaran ; Tetzlaff, Michael T. ; Frederick, Dennie T. ; Sullivan, Ryan J. ; Amaria, Rodabe N. ; Patel, Sapna P. ; Hwu, Patrick ; Woodman, Scott E. ; Glitza, Isabella C. ; Diab, Adi ; Vence, Luis M. ; Rodriguez-Canales, Jaime ; Parra, Edwin R. ; Wistuba, Ignacio I. ; Coussens, Lisa ; Sharpe, Arlene H. ; Flaherty, Keith T. ; Gershenwald, Jeffrey E. ; Chin, Lynda ; Davies, Michael A. ; Clise-Dwyer, Karen ; Allison, James P. ; Sharma, Padmanee ; Wargo, Jennifer A. / Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. In: OncoImmunology. 2016 ; Vol. 5, No. 3.
@article{377e23b2236b46d5bd01f0d9133fad20,
title = "Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma",
abstract = "ABSTRACT: We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, and we performed studies to test the hypothesis that clinical patterns and immune infiltrates differ at progression on these treatments. We observed rapid clinical progression kinetics in patients on targeted therapy compared to immune checkpoint blockade. To gain insight into possible immune mechanisms behind these differences, we performed deep immune profiling in tumors of patients on therapy. We demonstrated low CD8+T-cell infiltrate on targeted therapy and high CD8+T-cell infiltrate on immune checkpoint blockade at clinical progression. These data have important implications, and suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.",
keywords = "BRAF, CTLA-4, Immune checkpoint blockade, melanoma, PD-1, targeted therapy",
author = "Cooper, {Zachary A.} and Alexandre Reuben and Spencer, {Christine N.} and Prieto, {Peter A.} and Austin-Breneman, {Jacob L.} and Hong Jiang and Cara Haymaker and Vancheswaran Gopalakrishnan and Tetzlaff, {Michael T.} and Frederick, {Dennie T.} and Sullivan, {Ryan J.} and Amaria, {Rodabe N.} and Patel, {Sapna P.} and Patrick Hwu and Woodman, {Scott E.} and Glitza, {Isabella C.} and Adi Diab and Vence, {Luis M.} and Jaime Rodriguez-Canales and Parra, {Edwin R.} and Wistuba, {Ignacio I.} and Lisa Coussens and Sharpe, {Arlene H.} and Flaherty, {Keith T.} and Gershenwald, {Jeffrey E.} and Lynda Chin and Davies, {Michael A.} and Karen Clise-Dwyer and Allison, {James P.} and Padmanee Sharma and Wargo, {Jennifer A.}",
year = "2016",
month = "3",
day = "3",
doi = "10.1080/2162402X.2015.1136044",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

AU - Cooper, Zachary A.

AU - Reuben, Alexandre

AU - Spencer, Christine N.

AU - Prieto, Peter A.

AU - Austin-Breneman, Jacob L.

AU - Jiang, Hong

AU - Haymaker, Cara

AU - Gopalakrishnan, Vancheswaran

AU - Tetzlaff, Michael T.

AU - Frederick, Dennie T.

AU - Sullivan, Ryan J.

AU - Amaria, Rodabe N.

AU - Patel, Sapna P.

AU - Hwu, Patrick

AU - Woodman, Scott E.

AU - Glitza, Isabella C.

AU - Diab, Adi

AU - Vence, Luis M.

AU - Rodriguez-Canales, Jaime

AU - Parra, Edwin R.

AU - Wistuba, Ignacio I.

AU - Coussens, Lisa

AU - Sharpe, Arlene H.

AU - Flaherty, Keith T.

AU - Gershenwald, Jeffrey E.

AU - Chin, Lynda

AU - Davies, Michael A.

AU - Clise-Dwyer, Karen

AU - Allison, James P.

AU - Sharma, Padmanee

AU - Wargo, Jennifer A.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - ABSTRACT: We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, and we performed studies to test the hypothesis that clinical patterns and immune infiltrates differ at progression on these treatments. We observed rapid clinical progression kinetics in patients on targeted therapy compared to immune checkpoint blockade. To gain insight into possible immune mechanisms behind these differences, we performed deep immune profiling in tumors of patients on therapy. We demonstrated low CD8+T-cell infiltrate on targeted therapy and high CD8+T-cell infiltrate on immune checkpoint blockade at clinical progression. These data have important implications, and suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.

AB - ABSTRACT: We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, and we performed studies to test the hypothesis that clinical patterns and immune infiltrates differ at progression on these treatments. We observed rapid clinical progression kinetics in patients on targeted therapy compared to immune checkpoint blockade. To gain insight into possible immune mechanisms behind these differences, we performed deep immune profiling in tumors of patients on therapy. We demonstrated low CD8+T-cell infiltrate on targeted therapy and high CD8+T-cell infiltrate on immune checkpoint blockade at clinical progression. These data have important implications, and suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.

KW - BRAF

KW - CTLA-4

KW - Immune checkpoint blockade

KW - melanoma

KW - PD-1

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84961621847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961621847&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1136044

DO - 10.1080/2162402X.2015.1136044

M3 - Article

AN - SCOPUS:84961621847

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 3

ER -